1.75 semaglutide Wegovy (semaglutide) Injector 1.7 mg/0.75 mL, 4 Pens Per Box **Refrigerated Item** 1 receptor agonists WEGOVY FLEX TOUH Semaglutide 1.75MG

By the end of the PIONEER 6 trial, 35% of patients diabetes and obesity who were treated with semaglutide had lost more than 5% of their body weight, and 15% had lost more than 10%

It helps control appetite, reduces food intake, and improves insulin sensitivity

Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and is not recommended during pregnancy or breastfeeding

10.1016/S0140-6736(18)31773-2 53 OttmanN.GeerlingsS

Temporary dose reduction or treatment interruption may be necessary in cases of severe gastrointestinal symptoms with dehydration